In Brief: Schering-Plough
Executive Summary
Schering-Plough: NDA filed for mometasone furoate .1% and salicylic acid 5% ointment for treatment of chronic, moderate to severe psoriasis vulgaris in patients 12 years of age and older, company announces Feb. 18...